Posted by Michael Wonder on 23 May 2021
EU regulator backs extending approval for remdesivir for another year
21 May 2021 - The EMA on Friday recommended extending conditional marketing approval by a year for Gilead Sciences’ COVID-19 treatment, remdesivir, the only drug so far that has been authorised for use in the region.
The regulator said the CHMP found that benefits of the drug outweighed risks, although the company was required to submit more data by the end of the year for the next scheduled renewal.
